DTC
RLMD icon

Deep Track Capital’s Relmada Therapeutics RLMD Stock Holding History

Deep Track Capital’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-117,200
Closed -$4.34M – 71
2022
Q3 		$4.34M Buy
+117,200
New +$3.25M 0.2% 62

Other funds holding RLMD

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Deep Track Capital's RLMD Position: Q4 2024 in Review

Deep Track Capital sold out of Relmada Therapeutics (RLMD) in Q4 2024, closing a stake of 674,833 shares — an estimated $2.19M sold.

Deep Track Capital first reported a position in RLMD in Q1 2022 and held it in 11 quarters. The position peaked at $17.1M in Q3 2022. 48 funds tracked by Wall St. Rank hold RLMD as of Q4 2024.

  • Deep Track Capital reported no remaining Relmada Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Deep Track Capital sold 674,833 Relmada Therapeutics shares in Q4 2024, an estimated $2.19M.
  • Deep Track Capital first reported a position in Relmada Therapeutics in Q1 2022 and held it in 11 quarters.
  • Deep Track Capital's Relmada Therapeutics position peaked at $17.1M in Q3 2022.
  • 48 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2024.

Based on Deep Track Capital's 13F filing for Q4 2024, filed 14 Feb 2025.